- INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
- MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
- MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
- MannKind Repays Certain Debt Obligations
- MannKind Announces CFO Transition
- MannKind Corporation Announces Participation at Upcoming Conferences
- MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
- MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024
- MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million
- MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Friday, MannKind Corp (MNKD:NMQ) closed at 5.85, -3.15% below its 52-week high of 6.04, set on Jul 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.89 |
---|---|
High | 5.90 |
Low | 5.69 |
Bid | 5.85 |
Offer | 5.95 |
Previous close | 5.80 |
Average volume | 2.59m |
---|---|
Shares outstanding | 272.32m |
Free float | 266.77m |
P/E (TTM) | 249.68 |
Market cap | 1.59bn USD |
EPS (TTM) | 0.0234 USD |
Data delayed at least 15 minutes, as of Jul 26 2024 21:00 BST.
More ▼